There are fundamental differences in the pathogenesis and course of type 2 diabetes between young people and adults that necessitate a different approach in youth with the disease, with an emphasis on ...
Biomea Fusion presented positive data on icovamenib for type 2 diabetes, showing improved glycemic control and weight loss in clinical trials. Biomea Fusion announced promising new data for icovamenib ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback